Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000277.2(PAH):c.1012G>T (p.Asp338Tyr)

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA229269

102468 (ClinVar)

Gene: PAH

Condition: phenylketonuria

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: 2237dbe2-a983-4dcc-8838-57eb31ccb465

Approved on: 2020-11-09

Published on: 2022-02-20

HGVS expressions

NM_000277.2:c.1012G>T

NM_000277.2(PAH):c.1012G>T (p.Asp338Tyr)

NC_000012.12:g.102844389C>A

CM000674.2:g.102844389C>A

NC_000012.11:g.103238167C>A

CM000674.1:g.103238167C>A

NC_000012.10:g.101762297C>A

NG_008690.1:g.78214G>T

NG_008690.2:g.119022G>T

ENST00000553106.6:c.1012G>T

ENST00000307000.7:c.997G>T

ENST00000549247.6:n.771G>T

ENST00000551114.2:n.674G>T

ENST00000553106.5:c.1012G>T

ENST00000635477.1:n.116G>T

ENST00000635528.1:n.527G>T

NM_000277.1:c.1012G>T

NM_001354304.1:c.1012G>T

NM_000277.3:c.1012G>T

NM_001354304.2:c.1012G>T

NM_000277.3(PAH):c.1012G>T (p.Asp338Tyr)

Pathogenic

PM3_Very Strong PM2 PP4_Moderate

PP3 PM5

Evidence Links 3

Expert Panel

Phenylketonuria VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Phenylketonuria VCEP

The c.1012G>T (p.Asp338Tyr) variant in PAH has been reported in multiple individuals with PAH deficiency (BH4 deficiency excluded, PMID: 27121329, PMID: 21147011). This variant has an extremely low allele frequency in gnomAD (MAF=0.00002). This variant was detected with multiple pathogenic variants: p.P281L (PMID: 16601866); p.F299C (PMID: 7913581); p.I65T (PMID: 17502162); c.1066-11G>A (PMID: 31623983); p.Arg261*, p.Phe55Leu (PMID: 26655635). Multiple lines of computational evidence do not agree on predicted pathogenicity (Deleterious in SIFT, PolyPhen, Polymorphism in MutationTaster). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_very-strong, PM2, PP4_Moderate.

PM3_Very Strong

D338Y seen in trans with 2 pathogenic variants in 2 PKU patents (P281L, PMID: 16601866; F299C, PMID: 7913581) and with c.194T>C (p.I65T, P) parental analysis not reported PMID: 17502162; c.1066-11G>A (P), p.G352C (VUS) parental analysis not reported PMID: 31623983; p. [Arg261*]; [Asp338Tyr]; p.[Phe55Leu]; [Asp338Tyr] P/LP parental analysis not reported PMID: 26655635 4.0 pts

D338Y seen in trans with P281L (VarID 589, Pathogenic in ClinVar) in 1 patient with mild PKU. All the mutations identified were confirmed by analysing parental DNA. PubMed:16601866

Seen in 1 PKU patient. The mother of the proband carries the D338Y mutation; the paternal mutation is F299C (VarID 613, Pathogenic/LP in ClinVar). PubMed:7913581

PM2

Absent in 1000G, ESP. Extremely low frequency in ExAC (0.00001) and gnomAD (MAF=0.00002)

PP4_Moderate

D338Y was found in 3 PKU patients. A defect in the synthesis or regeneration pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels as well as by measuring the dihydropteridine reductase activity. PMID: 27121329, PMID: 21147011, PMID: 7913581

588 hyperphenylalaninemic patients were investigated. Assessment included PAH gene and genes of the BH4 synthesis/recycling pathways (PTS and QDPR). D338Y was found in one homozygous PKU patient. PubMed:21147011

Fifty-five PKU probands contributed DNA. A G->T transversion in codon 338 (D338Y) of exon 10 occurred on one French Canadian chromosome, is on Hp4, and abolishes a Hinfl site (fig. 1, middle). PubMed:7913581

PP3

Deleterious in SIFT, PolyPhen, Polymorphism in MutationTaster

PM5

Only variant in this codon in ClinVar

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.